Showing results (181-190 of 277) with videos related to

Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53Mansoor N Saleh, Manish R Patel, Todd M Bauer, et al.
British Journal of Cancer|November 6, 2022
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancerGiuseppe Curigliano, Geoffrey I Shapiro, Rebecca S Kristeleit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2016
Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell CarcinomaNicole G Chau, Yvonne Y Li, Vickie Y Jo, et al.
Molecular Cancer Therapeutics|December 5, 2024
First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid TumorsMelissa L Johnson, Beni B Wolf, Judy S Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2019
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP InhibitionKalindi Parmar, Bose S Kochupurakkal, Jean-Bernard Lazaro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid TumorsSara M Tolaney, Khanh T Do, Joseph P Eder, et al.
The New England Journal of Medicine|October 29, 2010
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumorJames E Butrynski, David R D'Adamo, Jason L Hornick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2026
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)Rana R McKay, Wanling Xie, Archana Ajmera, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 18, 2026
Regulation of the immune CD155-CD226-TIGIT axis by cyclin D-CDK4/6Anne Fassl, Miriam Palacios Espinoza, Deborah Butter, et al.
JCO Precision Oncology|July 9, 2025
LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair GenesSriram Anbil, Nicholas J Seewald, E Gabriela Chiorean, et al.
Pageof 28